Major Finding: Brain metastases that arise from various primary sites characteristically harbor chromosomal instability and an immunosuppressive stromal/immune composition.

First Disclosures in Molecular Cancer Therapeutics present drugs for the first time in published literature, accompanied by pertinent translational investigations. Submissions are assessed based on ...

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

1Division of Hematology/Oncology, Department of Medicine, University of Washington, Seattle, Washington. 2Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington. Search for ...

1Department of Oral and Maxillofacial-Head Neck Oncology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, College of Stomatology, Shanghai Jiao Tong University, ...

The FDA granted accelerated approval to the antibody–drug conjugate (ADC) telisotuzumab vedotin (Emrelis; AbbVie), which targets the receptor tyrosine kinase c-Met, for patients with locally advanced ...

1Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland. 2Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.

1Department of Cellular and Molecular Pharmacology, Cell Design Institute, University of California San Francisco, San Francisco, California.

The FDA has approved belzutifan (Welireg; Merck) for patients with locally advanced, inoperable, or metastatic pheochromocytoma or paraganglioma (together known as PPGL), rare neuroendocrine tumors ...